1.
Simpson E, Kircik L, Blauvelt A, Kuligowski M, Venturanza M, Sun K, Eichenfeld L. Long-Term Safety and Disease Control With Ruxolitinib Cream in Patients With More Severe Atopic Dermatitis: Pooled Results From Two Phase 3 Studies. J of Skin [Internet]. 2021Nov.5 [cited 2022Aug.11];5(6):s66. Available from: https://jofskin.org/index.php/skin/article/view/1417